Novavax (NVAX) CFO reports RSU vesting and 20,850 shares withheld for taxes

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity. On March 3, 2026, he acquired 43,167 shares of common stock through the exercise and vesting of restricted stock units at no cost. On the same date, 20,850 shares of common stock were withheld by the company at $9.49 per share to cover tax obligations, leaving him with 124,280 directly held common shares.

Insider Trade Summary

43,167 shares exercised/converted

Mixed 3 txns

Insider Kelly James Patrick

Role EVP, CFO and Treasurer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	43,167	$0.00	--
Exercise	Common Stock	43,167	$0.00	--
Tax Withholding	Common Stock	20,850	$9.49	$198K

Holdings After Transaction: Restricted Stock Units — 86,333 shares (Direct); Common Stock — 145,130 shares (Direct)

Footnotes (1)

Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 06:04 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly James Patrick

(Last)

(First)

(Middle)

21 FIRSTFIELD ROAD

(Street)

GAITHERSBURG

20878

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		M		43,167	A	$0	145,130	D
Common Stock	03/03/2026		F		20,850⁽¹⁾	D	$9.49	124,280	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	03/03/2026		M			43,167	⁽²⁾	03/03/2035	Common Stock	43,167	$0	86,333	D

Explanation of Responses:

1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.

2. One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date.

	/s/ Mark J. Casey, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Novavax (NVAX) CFO James Patrick Kelly report?

James Patrick Kelly reported RSU-related activity on March 3, 2026. He acquired 43,167 common shares from restricted stock units and had 20,850 shares withheld by Novavax at $9.49 per share to satisfy associated tax withholding obligations.

How many Novavax (NVAX) shares does CFO James Patrick Kelly hold after this Form 4?

After these transactions, James Patrick Kelly directly holds 124,280 shares of Novavax common stock. This reflects RSU vesting into 43,167 shares and the withholding of 20,850 shares by the company to cover tax liabilities tied to that vesting.

Was the Novavax (NVAX) CFO’s Form 4 transaction an open-market stock sale?

No, the Form 4 shows no open-market sale. Instead, 20,850 shares of common stock were withheld by Novavax at $9.49 per share to satisfy tax withholding requirements triggered by the vesting and conversion of restricted stock units on March 3, 2026.

What is the vesting schedule for the Novavax (NVAX) CFO’s restricted stock units?

The RSUs vest in three equal installments. One-third of the restricted stock units vests on each of the first three anniversaries of March 1, 2024, under Novavax’s 2015 Stock Incentive Plan, provided James Patrick Kelly remains continuously employed through each vesting date.

What do the M and F transaction codes mean in this Novavax (NVAX) Form 4?

Code M indicates the exercise or conversion of a derivative security, here RSUs becoming common stock. Code F reflects shares withheld by the issuer, with 20,850 shares of Novavax common stock used to pay tax withholding arising from the RSU vesting event.